The biopharmaceutical industry faces some major bottlenecks in the development lifecycle that can only be overcome by effective digital transformation. According to research by pharmamanufacturing.com, in excess of 60% of biopharma organizations are still managing many of their critical steps with paper and Microsoft Office, while struggling to integrate the expanding ecosystem of equipment and data – literarily wasting 30–40% of their time on basic data administration and documentation.
At the heart of the problem is the need for a digital transformation of the development lifecycle, because in a world of automation, parallelization and digitalization, the main barrier to accelerated biopharmaceuticals is – ironically – the fragility of a lifecycle managed with paper records and silos of data. Especially when contextualized data is the rocket fuel needed to drive speed and innovation.
We accepted the challenge and created a BioPharmaceutical Lifecycle Management (BPLM) system that integrates data from all instruments, all equipment and all software to shorten time to market for biopharmaceuticals like vaccines and therapies.
IDBS polar accelerates biopharmaceutical development into the digital age with a unique software platform designed to remove roadblocks and deliver deep insights that drive innovation – for faster and more cost-effective access to life changing therapies.
IDBS Polar is the world’s first BioPharmaceutical Lifecycle Management (BPLM) system – a cloud-based platform that eliminates repetitive manual tasks, allowing you to efficiently execute your processes while curating the data you need to reduce time-to-market by tackling the biggest challenges in process design, optimization, scale-up and technology transfer.
IDBS Polar rests upon three pillars: best practice out-of-the-box workflows exclusively designed for biopharma development, full integration of all systems and equipment for access to your complete data continuum, and advanced tools for fast analytics, insight and technology transfer based on high-quality, contextualized data.
The result is a dramatic reduction of time to market by up to three years, and a much greater potential to continuously learn, model, simulate and predict the future to further improve development cycles.
Fast deployment and up to six times shorter time to value than traditional software platforms.
Key benefit
Dramatically reduced time-to-market
Key benefit
Full integration of all systems and equipment for contextualized, high-quality data
Key benefit
Best practice out-of-the-box workflows exclusively designed for biopharma development
Key benefit
Advanced tools for meaningful analytics and faster insights
Key benefit
Faster technology transfer
Key benefit
Improved modelling & simulation for predictive value
Key benefit
Fast deployment and 6 times shorter time-to-value
3B Pharmaceuticals has become a leading player in the discovery and development of innovative radiopharmaceutical cancer medicines and diagnostics. Building on its core expertise in peptide drug discovery 3BP has developed a broad product pipeline of which several programs…
Goldfinch Bio is a cutting edge, fast-growing biotechnology company that is singularly focused on discovering and developing precision therapies for kidney disease. Just as the goldfinch was a prominent figure of the Renaissance, Goldfinch Bio is leading a new…
Sealy Inc. improves efficiency and promotes corporate compliance with E-WorkBook, leading to significant productivity gains across the Company. The challenge Previously using paper lab notebooks, Sealy Inc. found that its data was not being fully utilized and the company…
IDBS and the University of Cambridge join forces for cheminformatics tools; captures and leverages IP with IDBS E-WorkBook for chemistry The challenge The Department of Chemistry needed a data management solution to support its broad research areas and ongoing…
